When GlucoLight was founded in 2003 to bring to market an optical platform for non-invasive glucose monitoring-specifically, optical coherence tomography-its founders decided to set themselves apart from the pack in two ways. First, they would focus on generating clinical data, and letting that data speak for itself. The company has conducted six clinical trials to date. Second, they would validate its platform in an emerging market that needs a technological solution but that is well-validated from the clinical perspective: glucose monitoring in the hospital critical care environment. This market also offers a faster time to market because there is no requirement to miniaturize the monitor for the ICU environment. Part of a group of articles that includes: "Where are They Now? Checking in on Three Glucose Monitoring Companies," "A Decade of Development of SMSI: Will it Yield Improved Accuracy in CGM?" and "Pelikan Swoops in on the Big Four."
Although venture capitalists are the shepherds of large pools of
risk capital, they really don’t like to have to take anything
on faith. So it doesn’t help that non-invasive consumer
glucose monitoring is often referred to as the "Holy Grail" in
diabetes care. Does the Holy Grail really exist? After 10 to 15
years of investing in the field, investors have witnessed many
failures and not a single success, and they have often found
themselves supporting companies that even after 10 years remain in
the development phase. Very few are believers any more.
That’s why, when GlucoLight Corp. was founded in 2003 to bring to market an optical platform for non-invasive glucose...
